ACE-031 is sold here for laboratory research, in 1 size (1mg), starting at $60.00 a vial. Every batch arrives with a certificate naming the test that identified it, the test that measured its purity, and the date each was run. It is not an FDA-approved medicine. Research use only, and never for people or animals.
ACE-031 specifications
| Product name | ACE-031 |
|---|---|
| Also sold as | ACE-031 peptide, ramatercept |
| Physical form | Freeze-dried powder — a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 1mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | At the laboratory — each certificate posts here the day it clears |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California — same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is ACE-031?
ACE-031 is also listed and searched as ACE-031 peptide, ramatercept. They all mean the same compound. Supplier lists write it as peptide ACE-031 as well; every one of those is this record. A name is not a test, which is why the lot record further down counts for more than the wording on a label.
Fusion protein of the activin receptor type IIB extracellular domain with an IgG1 Fc region — a soluble receptor decoy, not a peptide.
Binds myostatin and related TGF-beta superfamily ligands in circulation, preventing them from reaching activin type II receptors and thereby removing their inhibitory signal on muscle.
Developed by Acceleron Pharma and tested in a randomised, double-blind, placebo-controlled ascending-dose trial in ambulatory boys with Duchenne muscular dystrophy.
No approved product. The clinical trial was stopped early over safety findings, and the efficacy trends reported were not statistically significant.
ACE-031 for sale: 1mg vials, price per mg
ACE-031 is sold in 1 size here, 1mg, from $60.00 a vial. The per-mg column is the honest comparison between sizes; the two tier columns show what ten and twenty vials of one size bill at, because the volume discount is per size and mixed sizes do not combine.
| Size | One vial | Per mg | 10 vials −10% | 20 vials −15% | Availability |
|---|---|---|---|---|---|
| ACE-031 1mg | $60.00 | $60.00 | $540.00$54.00/mg | $1,020.00$51.00/mg | Backordered — waitlist |
ACE-031 discounts: bulk pricing, Subscribe & Save, and codes
Three things move this price and nothing else does: how many vials of one size are on the order, whether that order repeats, and one code. The fourth column prices each route against the 1mg vial.
| Buying option | Takes off | When it applies | 1mg at this option |
|---|---|---|---|
| One vial, one time | — | Any order | $60.00 |
| 10–19 vials of one size | 10% | This order | $540.00$54.00 a vial |
| 20 vials of one size | 15% | This order | $1,020.00$51.00 a vial |
| Subscribe, every 1 month | 6% | Shipment 2 onward | First $60.00, then $56.40 |
| Subscribe, every 2 months | 4% | Shipment 2 onward | First $60.00, then $57.60 |
| Subscribe, every 3 months | 2% | Shipment 2 onward | First $60.00, then $58.80 |
| 10 vials on a monthly subscription | 10%, then 6% more | Shipment 2 onward | First $540.00, then $507.60 |
| Sign-up code | 10% of the order | One use, dead 24 hours after signup | $54.00 for one vial |
| Friday newsletter code | 5% of the order | Live 24 hours, a new one each Friday | $57.00 for one vial |
| On-site offer code | 5% of the order | Live 30 minutes from when it appears | $57.00 for one vial |
| Free standard shipping | The shipping charge | Orders over $200 | 4 vials |
The first three stack; the codes do not. A volume discount comes off the line, a subscription cadence comes off that same line from shipment 2, and one code comes off what is left. One code per order, never two. A subscription runs a minimum of two shipments and can be cancelled once the second has shipped, and the first shipment always bills at today's eligible price with no cadence discount on it. The lowest this record ever bills is $47.94 per mg: twenty 1mg vials on a monthly subscription, from shipment 2 onward.
Every figure above is what you pay; nothing is added at checkout — dispatch and delivery work the same on every order.
Where to buy ACE-031: five checks before you order from anyone
ACE-031 for sale, or ACE-031 peptide for sale, means this page: one record, 1 size, a lot certificate for each. You can buy ACE-031 online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Run these on us too. A supplier who cannot pass them is asking you to take their word for it, and their word is the one thing a certificate exists to replace.
- Check the certificate on the lab’s own site, not ours.
- See whether it was written for the seller.
- Match the lot number on the paper to the one on the vial.
- Look for a method and a date next to every number.
- Make sure identity was tested, not assumed.
Each of those is worked through, with what a failed check actually looks like, on verifying a certificate.
The ACE-031 certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run — how to read one covers what each field does and does not cover. ACE-031 (ramatercept) is a FUSION PROTEIN: the extracellular domain of activin receptor type-2B joined to an antibody Fc region. UniProt Q13705 is the receptor it derives from, not the fusion, which is a larger glycosylated protein whose mass the lot certificate reports. So the mass on the lot certificate is the one to read; a listing that quotes the published figure for this material is quoting the wrong molecule.
The certificate below belongs to one lot, and its number matches the one printed on the vial you receive. A real report for a different batch is still the wrong report.
| Size | Lot | Identity method | Purity | Test date |
|---|---|---|---|---|
| 1mg | Pending verification | Pending verification | Pending verification | Pending verification |
No lot documentation is published for ACE-031 yet. Rather than display a placeholder certificate, this record shows the gap until each field has been verified against the lot in hand. The certificate index lists every lot the moment its report clears.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to ACE-031.
Where the FDA stands on ACE-031
The FDA has not approved this compound for anything, and nothing in this catalogue is a medicine. Where a compound stands legally depends on what it is, what form it is in, what it is being used for and which country you are in, and it changes over time, so the status shown here carries the date it was last checked.
Status verified 2026-08-25. Regulatory positions move; check the primary source before relying on any summary, including this one.
It is sold here as laboratory material under the research-use restriction that closes this page, which is not an approval, and not a statement that the compound is safe, effective or right for any purpose.
ACE-031 research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarise what it found. A supplier is not a neutral judge of evidence about its own catalogue.
ACE-031 is not a peptide but a fusion protein: the extracellular ligand-binding domain of activin receptor type IIB joined to an IgG1 Fc. It works as a decoy, mopping up myostatin and related ligands before they can signal. That mechanism is deliberately broad — activin type II receptors bind several TGF-beta superfamily members, not myostatin alone — and the breadth is the likely explanation for what happened in the clinic. The compound produced effects outside muscle, and those effects, rather than any lack of muscle activity, ended the programme.
| Reported observation | Model | Source |
|---|---|---|
| In a randomised, double-blind, placebo-controlled ascending-dose trial in ambulatory boys with Duchenne muscular dystrophy, the study was STOPPED after the second dosing regimen over potential safety concerns of epistaxis and telangiectasias. Trends were reported for maintenance of six-minute walk distance against a decline in placebo, and for increased lean body mass and bone mineral density with reduced fat mass — but the walk-test trend was not statistically significant. The authors record that non-muscle-related adverse events contributed to the decision to discontinue. | randomised double-blind placebo-controlled ascending-dose trial, ambulatory boys with Duchenne muscular dystrophy | Campbell and colleagues, Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial, Muscle and Nerve (2016)Sponsor co-authored with academic investigators. The trial-stopping events are the material finding, not the efficacy trends. |
| The target rationale rests on myostatin being a negative regulator of skeletal muscle growth: mice with the GDF-8 gene disrupted show a widespread increase in muscle mass through hyperplasia and hypertrophy. | gene targeting in mice | McPherron, Lawler and Lee, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature (1997) |
Open questions. The defining fact about ACE-031 is that its clinical trial was halted early over safety, specifically nosebleeds and telangiectasias — small dilated vessels visible in the skin. Those are vascular findings, not muscle findings, and they are consistent with the decoy binding TGF-beta superfamily ligands beyond myostatin. Any account of this compound that reports the lean-mass and bone-density trends without the discontinuation is describing half of a published result. The efficacy signals themselves were trends and the walk-test difference did not reach significance.
There is no approved product, and the programme did not continue. Note also that this is a large Fc fusion protein rather than a peptide, which has consequences for handling, stability and what an identity assay on a lot would even involve.
Each row above describes an observation in the stated model. None of it describes what ACE-031 would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
Questions about ACE-031
Where to buy ACE-031 Peptide, and can I get it online?
How much does ACE-031 Peptide cost?
What is the cheapest way to buy ACE-031 Peptide?
What is ACE-031 used for?
What is ACE-031 peptide?
How do I verify the certificate of analysis is real?
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
